cyrilzakka/clinical-trials huggingface dataset:
Impact of an Intervention of Screening, Treatment Initiation and Referral to PROmote Smoking CEssation in Emergency Department Patients

Smoking cessation assistance is one of the major issues in prevention policies because the prevalence of smoking remains high in France. With its numerous consultations, an emergency service seems to be an interesting place for setting up and helping with weaning, despite specific working conditions. The study, which is a pilot, is interested in the feasibility and efficacy of the implementation of a STIR (Screening, Treatment Intervention and Referral) protocol, which screening, brief intervention, nicotine replacement therapy and referral to a specialist in order to help the patients in smoking cessation.

Individual randomization as soon as the patient gives his consent and meets the inclusion - non-inclusion criteria.

Control group: delivery of the "tobacco-info-service" brochure titled "Why quit smoking? ", then phone call at 7 days and a month to collect tobacco consumption. Visit for 3 month. Intervention group: STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the "tobacco-info-service" brochure, initiation of a nicotine replacement therapy with nicotine patches made by a trained emergency nurse or doctor, then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months.

In both groups: collection of the primary endpoint during the M3 visit. For patients who did not come (regardless of the group):

call for collection of the main judgment criterion

Carers will be included and will sign a consent form once the eligibility criteria have been checked and consent has been signed. They will be asked to complete an adherence questionnaire (Likert scale) regarding smoking prevention in emergency departments before the start of the study and after the last patient follow-up has taken place.

Eligibility Criteria:
Inclusion Criteria:

* Age \>= to 18 years old
* Active smoker defined by having smoked at least 100 cigarettes in total in his life, associated with daily consumption or weekly
* Free and informed consent signed by the patient
* Patient with an understanding of the French language to participate in the intervention if necessary
* Patient affiliated to a social security regimen

Care giver inclusion criteria:

* Age ≥ 18 years
* Caregiver working in one of the 3 departments participating in the study
* Signature of free and informed consent

Exclusion Criteria:

* Absolute vital emergency
* Pregnant or breastfeeding women
* Contraindication to taking nicotine
* Taking nicotine by patch or gum or e-cigarette
* Patient under AME (national medical insurance)
* Patients under guardianship
Stress-induced Vascular Dysfunction: Evaluation of Endothelial Function in a Cohort of Patients With Takotsubo Syndrome

The aim of this prospective single-center study is to evaluate endothelial function, arterial compliance, sympathetic nervous activity at rest and after mental and physical stress, carotid atherosclerosis, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.

The aim of this prospective single-center study is to evaluate endothelial function, arterial compliance, sympathetic nervous activity at rest and after mental and physical stress, carotid atherosclerosis, oxidative stress parameters, quality of life and platelet adhesion in patients with Takotsubo Syndrome (apical ballooning syndrome/broken heart syndrome) and age-matched controls.

Eligibility Criteria:
Inclusion criteria: We plan to include male or female subjects, age 18-80 with a diagnosis of Takotsubo Syndrome (according to standard clinical criteria\[Strony, J., et al., Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol, 1993. 265(5 Pt 2): p. H1787-96.\]) in the last 10 years.

Moreover, patients matched to the Takotsubo patients for age and cardiovascular risk factors will be included in the control group.

All patients will signed an written informed consent

Exclusion criteria:

* Long acting nitrates, or PDE-5-Hemmer
* Alcohol or drug abuse,
* Malignancy (unless healed or remission \> 5 years)
* Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)
* Pulmonary Hypertension
* Participation in another study within the last month
Comparison Between Single Shot Ultrasonographic Guided Fascia Iliaca Block and Quadratus Lumborum Block in Hip Arthralgia. Comparative Double Blind Study

hip arthralgia is a painful condition specially geriatric patients. Trail to alleviate pain using locoregional procedures

hip arthralgia is a common presentation in many conditions as rheumatoid arthritis, systemic lupus . Pain is agonizing and disabling patinet to have normal life. we are considering fascial plane block versus quadratus lumborum block to dampen pain score.

Eligibility Criteria:
Inclusion Criteria:

* All candidates with hip arthalgia (primary or secondery)

Exclusion Criteria:

* History of warfarin or clopidogrel adminstration .
* patient on chemotherapy
* Cognitive disrder
Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study

The investigators conducted a pre-post naturalistic study regarding changes observed associated with a 15-week course of an adapted form of dialectical behaviour therapy for adolescents. We measured frequency of self-harm prior to treatment and after treatment using the Self-Injurious Thoughts and Behaviors Interview. We also measured changes using the Suicide Ideation Questionnaire, Life Problems Inventory, Resiliency Scale for Children and Adolescents.


Eligibility Criteria:
Inclusion Criteria:

* features of Borderline Personality Disorder (BPD) and recent history of self-injurious thoughts or behaviours.

  1. meeting criteria for BPD or for subsyndromal variants of BPD, and (2) self-injurious thoughts and behaviours defined as: (a) a score \> 30 on the Suicidal Ideation Questionnaire (SIQ) OR (b) Deliberate Self-harm in the 4 months prior to treatment

Exclusion Criteria:

* severe substance use (where residential treatment would be indicated), florid psychosis and developmental delay
Measuring Renuvion Soft Tissue Contraction Using Ultrasound

This is a prospective, single-center, non-randomized study of up to 5 subjects who are receiving treatment with the Renuvion APR system following power-assisted liposuction in the abdomen per investigator standard of care. Ultrasound images of soft tissue contraction will be taken on abdomen prior to and during the procedure. Measurements of contraction will be calculated from the ultrasound images by an ultrasonographer. All adverse events and expected treatment effects will be documented.

Follow-up photographs and ultrasound images will be captured at D30, D45, D60, D90, D180, D270, \& D365.

This is a prospective, single-center, non-randomized study of up to 5 subjects who are receiving treatment with the Renuvion APR system following power-assisted liposuction in the abdomen per investigator standard of care. Subjects may also have other body areas treated at the same time. Demographic information, medical history, and procedure details will be documented. Pre- and post-procedure care are per investigator standard of care and documented. Video may be taken during the procedure.

Ultrasound images of soft tissue contraction will be taken on abdomen prior to and during the procedure. Measurements of contraction will be calculated from the ultrasound images by an ultrasonographer. At baseline, photographs will be taken of the treatment areas. Surface area measurements will be taken of each treatment area prior to study treatment.

Post-procedure care will be as per investigator standard of care and documented. All adverse events and expected treatment effects will be documented.

Follow-up photographs and ultrasound images will be captured at D30, D45, D60, D90, D180, D270, \& D365.

Eligibility Criteria:
Inclusion Criteria:

* Patients who are scheduled for a procedure involving the use of Renuvion for the contraction of subcutaneous soft tissue. Patients undergoing procedures involving Renuvion alone and/or Renuvion following liposuction will be included.
* Patients who have acceptable cardiopulmonary health for outpatient surgery.
* Willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits.
* Willing to release rights for the use of study photos, including in potential publication.
* Able to communicate with the site via video and/or photographs, in the event of a virtual follow-up visit.
* Able to read, understand, sign and date the informed consent document (English only).

Exclusion Criteria:

* BMI of greater than 35.
* Diabetes mellitus with A1C score \>7.
* Active cigarette smokers or nicotine vape users.
* History of connective tissue disease (Ehlers Danlos, Cutis Laxa, Pseudoxanthoma Elasticum, Marfan's, etc.)
* Patients who, in the opinion of the investigator, is not an appropriate candidate for the study.
* Patients requiring a concomitant procedure in the Renuvion treatment area that could impact the ultrasound measurements or the effectiveness results.
Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women

The purpose of this study is to evaluate whether trastuzumab and letrozole are effective and safe in the preoperative treatment for postmenopausal patients with hormone receptor-positive and HER2-positive breast cancer.

Eligibility criteria

* Ages Eligible for Study: ≥ 20 years
* Invasive cancer (clinical stage IB-IIIB)
* Measurable tumor larger than 1cm
* ECOG status 0 or 1
* Postmenopausal women

  * Age ≥55 years and amenorrhea
  * Age \<55 years and amenorrhea for ≥12 months with FSH \>30 mIU/ml
* HER2 positive tumor

  * 3 positive on IHC
  * 2 positive on IHC with HER2 gene amplification on FISH or SISH using a single-probe or dual-probe
* Estrogen receptor positive tumor

  * Positive ER expression with Allred score more than PS3/TS8 or modified Allred score more than PS4/TS7
* Eligible cardiac function

  * Normal heard evaluated by ECG

    * Consider clinically non-significant arrythmia and ischemic change as normal
  * LVEF ≥ 55% measured by ECHO or MUGA scan

Outcome measures

* Primary End-point

  * The rate of pathologic complete response (pCR)

    * No residual invasive cancer in breast
* Secondary End-point

  * Clinical Response Rate
  * Safety profiles for the preoperative use of concurrent trastuzumab and letrozole
  * The rate of breast conservative surgery
  * Total pathologic complete response (tpCR)

    * No residual invasive cancer in breast and ipsilateral axilla
  * Analysis of biomarkers based on baseline specimen and residual tumor
* Ki67 expression
* cDNA microarray: gene expression profiling
* Association between clinical response rate and circulating tumor cells (CTCs)

  * CTCs are measured by CytoGen (SEOUL, KOREA)"

Eligibility Criteria:
Inclusion Criteria:

* Invasive cancer (clinical stage IB-IIIC)
* Measurable tumor larger than 1cm
* ECOG status 0 or 1
* Postmenopausal women

  * Age ≥55 years and amenorrhea
  * Age \<55 years and amenorrhea for ≥12 months with FSH \>30 mIU/ml
* HER2 positive tumor

  * 3 positive on IHC
  * 2 positive on IHC with HER2 gene amplification on FISH or SISH using a single-probe or dual-probe
* Estrogen receptor positive tumor

  * Positive ER expression with Allred score more than PS3/TS8 or modified Allred score more than PS4/TS7
* Eligible cardiac function

  * Normal heard evaluated by ECG

    * Consider clinically non-significant arrythmia and ischemic change as normal
  * LVEF ≥ 55% measured by ECHO or MUGA scan

Exclusion Criteria:

* Inflammatory breast cancer
* Bilateral breast cancer
* Patients with previous breast cancer history
* Patients with previous breast cancer treatment: Generally include hormone therapy, chemotherapy, and radiotherapy)
* Patients having uncontrolled heart problems

  * Ischemic heart disease within 6 months
  * Congestive heart failure more than NYHA class II
  * Unstable angina
  * Clinically significant pericarditis
  * Amyloid heart disease
Nutritional Status After Sleeve Gastrectomy in Morbid Obesity: 6-Month Study

This study aims to evaluate the nutritional status of morbidly obese patients following gastric bypass surgery. Data from 76 patients aged 19-64, who will be monitored by a dietitian for at least six months, will be analyzed. Preoperative and postoperative biochemical parameters along with anthropometric measurements will assess.

Objective: This retrospective study aims to evaluate the nutritional status of morbidly obese patients in the first six months following sleeve gastrectomy.

Methods: The study is planned as a retrospective analysis. The data of 76 patients aged 19-64 years who underwent bariatric surgery and were monitored by a dietitian for at least six months will be included in the study. Preoperative and postoperative biochemical parameters and anthropometric measurements of the patients will be collected and analyzed.

Detailed Description: The study will assess the changes in nutritional status, including body weight, BMI, fasting blood glucose, HbA1c, Homa-IR, iron levels, vitamin D levels, and lipid profile (triglycerides, LDL, HDL) among morbidly obese patients in the first six months following sleeve gastrectomy. Preoperative and postoperative measurements will be compared to evaluate the impact of surgery on these parameters.

Conclusion: Results will be analyzed and interpreted after data collection is completed, and conclusions will be drawn accordingly.

Eligibility Criteria:
Inclusion Criteria:

* Data of patients aged 19-64 years
* Data of patients with BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 and at least one comorbidity such as obesity-related hypertension, dyslipidemia, type 2 diabetes mellitus, and sleep apnea
* Data of patients who underwent sleeve gastrectomy
* Volunteering

Exclusion Criteria:

* Data of patients who were not deemed suitable for surgery by the physician and to whom a surgical technique different from sleeve gastrectomy was applied
* Data of patients who were not followed up by a dietitian for six months after surgery
* Data of patients with gastrointestinal inflammatory bowel disease
* Data of patients with psychiatric disorders diagnosed by a physician
* Data of patients with cancer, pregnant and lactating women, alcohol or drug addiction
Modified Laparoendoscopic Rendezvous for Secondary Choledocholithiasis: a Nonrandomized Controlled Clinical Study

This study intends to explore the success rate and clinical efficacy of modified LERV in the treatment of patients with non-dilated common bile duct (internal diameter ≤10mm) through a non-randomized controlled clinical trial, and to clarify whether modified LERV can be used as the preferred routine treatment for choledocholithiasis secondary to gallbladder stones.

Patients with cholecystolithiasis secondary to common bile duct stones requiring surgical treatment during a 3-year period from 2022-6-1 to 2025-3-31 were enrolled in this non-randomized controlled clinical trial. Preoperative diameter of the middle common bile duct was determined by magnetic resonance cholangiography (MRCP) or B-ultrasound measurement. The actual treatment plan of the patients was recorded, including LERV treatment and ERCP+LC treatment. The baseline data and the success rate of stone removal, operation time, postoperative stone residual rate, complication rate, length of hospital stay and hospitalization cost were recorded for observation and follow-up. To determine whether modified LERV can be used as the preferred routine treatment for choledocholithiasis secondary to gallbladder stones.

Eligibility Criteria:
Inclusion Criteria:

1、18 years ≤ age \<85 years 2、clinical diagnosis of choledocholithiasis secondary to cholecystolithiasis and middle choledocholithiasis (MCBD) diameter ≤10mm; The diameter of MCBD was based on MRCP measurements. If MRCP could not be performed, CT images were used as reference, and B-ultrasound measurements were used as the standard.

3、 Good cardiopulmonary function, anesthesia evaluation tolerance under general anesthesia laparoscopic + endoscopic surgery.

-

Exclusion Criteria:

1、 Intrahepatic bile duct stones with indications for surgery, and need simultaneous surgery; 2、 Patients with choledocholithiasis \>2 cm or a large number of stones were difficult to remove; 3、 Patients with malignant hepatobiliary and pancreatic tumors or biliary tract malformations; 4、 Severe patients with severe pancreatitis and septic shock before operation; 5、Patients with previous gastric and duodenoscopic surgery history and interruption of gastroduodenal continuity; 6、 Severe partial stenosis of the upper gastrointestinal tract (from the oral cavity to the second duodenum), which is expected to be inaccessible to the duodenoscope.

-
Intermittent Catheterization in Spinal Cord Injured Men

The aim of this investigation is to study how the position of different catheters affect drainage of the bladder.


Eligibility Criteria:
Inclusion Criteria:

* Has given written informed consent
* Is at least 18 years of age and has full legal capacity
* Is a male
* Has an Spinal Cord Injury diagnosis

Exclusion Criteria:

* Participating in other interventional clinical investigations or have previously participated in this investigation
* Known hypersensitivity toward any of the test products
* Serious abdominal scars
* Symptoms of urinary tract infections
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device.

Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.

This study is a single site pilot comparative imaging study in which enrolled participants will undergo dilated fundus exam as per standard of care. Study images will be obtained using Optos ultrawide field fundus autofluorescence (FAF) and both blue and green ultrawide field FAF with Zeiss Clarus. Autofluorescence (AF) imaging will also be performed on the Spectralis as it is currently the gold standard. The goal will be to obtain all images in 60-75 minutes over one visit. Images will be assessed, and area of geographic atrophy measured independently by two experienced readers.

Eligibility Criteria:
Inclusion Criteria:

* 50 years or older and may be either male or female and may be of any race
* Established diagnosis of GA due to AMD
* GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation
* Willing to participate as evidenced by signing the written informed consent

Exclusion Criteria:

* Unable to tolerate opthalmic imaging
* Presence of neovascular AMD on OCT as confirmed by an ophthalmologist
* Presence of significant media opacity preventing adequate retinal imaging
* Presence of concurrent retinal disease which may confound assessment
Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma

Silicosis, a preventable yet irreversible occupational lung disease, has an insidious onset with a latency period for diagnosis extending beyond 10 years from the initial exposure. The central hypothesis of this study is that silicosis cases may currently be going undetected. The long-term goal of this research is to determine the current prevalence and forecast the future prevalence of silicosis and other pneumoconiosis among working populations in Oklahoma and to assist the public health and the healthcare system in planning for a potential resurgence of silicosis.


Eligibility Criteria:
Inclusion Criteria:

* Male 30 years or older
* Past or present employment in dusty environment, exposed to dust at work
* Ability to consent and answer the questionnaire

Exclusion Criteria:

* Female
* Never exposed to dusty environment or never exposed to dust at work
* Inability to consent and answer the questionnaire
* Age 29 years or younger
Effects of Antarctic Environment on Vitamin D Status and Health Risk Biomarkers of Its Inhabitants

The purpose of this study is to evaluate vitamin D (VD) deficiency in the population of Chilean Antarctica and evaluate the efficacy and safety of VD supplementation to decrease VD deficiency and favorably influence biomarkers for bone, cardiovascular, and immune health risk in the inhabitants of Chilean Antarctica.

The present study consists of an initial cross-sectional evaluation of VD status and specific health biomarkers in inhabitants of Chilean Antarctica, followed by a randomized controlled trial evaluating two acceptable approaches of vitamin D supplementation (cholecalciferol 600 IU daily vs. 25000 IU weekly) in Antarctic inhabitants.

Eligibility Criteria:
Inclusion Criteria:

* population of all ages living in the Chilean Antarctic territory during at least 3 months.

Exclusion Criteria:

* acute or chronic renal disease
* hyper or hypocalcemia
* osteomalacia or Paget's disease of bone
* use of VD supplements or fish oil supplements in the past month in doses higher than 400 IU daily
* treatment for known VD deficiency in the last 6 months
* UV phototherapy in the past month.
The Acute Effect of Interval-walking

Four months of interval walking training (IWT) is superior to energy-expenditure matched continuous walking training (CWT) with regards to weight loss and improvements in glycemic control. The reason for this is unclear. One potential explanation for the differential outcome in weight loss is excess post-exercise oxygen consumption (EPOC), which is defined as the elevated oxygen consumption measured during the hours following an exercise bout. A large EPOC means greater energy expenditure which, if energy intake does not change, leads to a greater weight loss. This weight loss may subsequently improve glycemic control

* Aim 1: To assess the effect of an acute bout of IWT vs. an acute bout of CWT on glycemic control in type 2 diabetics and to assess mechanisms responsible for differences (if any). It is hypothesised that IWT will be more advantageous for improving glycemic control.
* Aim 2: To examine the effect of an acute bout of IWT vs. an acute bout of CWT on EPOC. It is hypothesised that IWT will produce an EPOC of larger magnitude than CWT.


Eligibility Criteria:
Inclusion Criteria:

* Diabetes mellitus, type 2

Exclusion Criteria:

* Smoking
* Pregnancy
* insulin dependence
* Contraindication to physical activity (as judged by medical history and screening)
* Evidence of thyroid, liver, lung, kidney or heart disease